Investors & Media

Press Releases

Date Title and Summary Additional Formats
Toggle Summary ImmunoGen to Present New Data on IMGN632 at 61st ASH Annual Meeting
Updated Phase 1 Data to be Highlighted in Oral Presentation Demonstrate Tolerable Safety Profile and Encouraging Activity in AML and BPDCN Preclinical Data for IMGN632 in Combination with Azacitidine and Venetoclax Support Clinical Evaluation of Doublets and Triplet in AML WALTHAM, Mass.
View HTML
Toggle Summary ImmunoGen Reports Recent Progress and Third Quarter 2019 Financial Results
Full Mirvetuximab Soravtansine Phase 3 FORWARD I and Initial Phase 1b FORWARD II Triplet Data Presented at ESMO Phase 3 MIRASOL Trial for Mirvetuximab in Ovarian Cancer on Track to Start by Year-End Updated IMGN632 AML and BPDCN Monotherapy Data Accepted as Oral Presentation at ASH Conference Call
View HTML
Toggle Summary ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2019 Operating Results
WALTHAM, Mass. --(BUSINESS WIRE)--Oct. 18, 2019-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m.
View HTML
Toggle Summary ImmunoGen Presents Initial Data from Phase 1b FORWARD II Triplet Cohort Evaluating Mirvetuximab Soravtansine in Combination with Carboplatin and Avastin® at ESMO
  FORWARD II Triplet Combination Demonstrates Encouraging Anti-Tumor Activity     Preliminary Findings Support Ongoing Study in Platinum-Sensitive Patients     WALTHAM, Mass. --(BUSINESS WIRE)--Sep. 29, 2019-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug
View HTML
Toggle Summary ImmunoGen Presents Full Data from Phase 3 FORWARD I Study of Mirvetuximab Soravtansine in Ovarian Cancer at ESMO
  FORWARD I Did Not Meet Primary Endpoint of Progression-Free Survival; Promising Efficacy Results Seen in Folate Receptor Alpha (FRα) High Patients     Favorable Tolerability and Differentiated Safety Profile Observed with Mirvetuximab Monotherapy Compared to Chemotherapy     Exploratory Analyses
View HTML
Toggle Summary ImmunoGen to Present Full Data from Phase 3 FORWARD I Study of Mirvetuximab Soravtansine and Initial Data from Phase 1b FORWARD II Triplet Cohort at ESMO
Conference Call to be Held at 8 a.m. ET on Monday, September 30 WALTHAM, Mass. --(BUSINESS WIRE)--Sep. 17, 2019-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that full data and additional exploratory
View HTML
Toggle Summary ImmunoGen Reports Recent Progress and Second Quarter 2019 Financial Results
Registration Study for Mirvetuximab Soravtansine in Ovarian Cancer on Track to Start by Year-End Full Data from the Phase 3 FORWARD I Trial and Initial FORWARD II Triplet Data to be Presented at ESMO Recommended Phase 2 Dose and Schedule for IMGN632 Determined; Combination and MRD+ Protocol Filed
View HTML
Toggle Summary ImmunoGen Announces Conference Call to Discuss Its Second Quarter 2019 Operating Results
WALTHAM, Mass. --(BUSINESS WIRE)--Jul. 18, 2019-- ImmunoGen, Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m.
View HTML
Toggle Summary ImmunoGen Announces Completion of Operational Review
Company Will Prioritize Continued Development of Mirvetuximab Soravtansine and a Select Portfolio of Earlier-Stage Candidates Cash Runway Extended Through Readout of Mirvetuximab Soravtansine Pivotal Trial in Ovarian Cancer Conference Call to be Held at 8 a.m. ET Today WALTHAM, Mass.
View HTML
Toggle Summary ImmunoGen Announces Mature Data from FORWARD II Expansion Cohort Evaluating Mirvetuximab Soravtansine in Combination with Avastin® in Ovarian Cancer
Results to be Presented at 2019 ASCO Annual Meeting Combination Demonstrates Significant Anti-Tumor Activity and Favorable Safety and Tolerability in Platinum-Resistant Disease Findings Support Ongoing Studies of Doublet Combination in Platinum-Agnostic Disease and Triplet in Platinum-Sensitive
View HTML